Is there a role for immunotherapy in HER2-positive breast cancer? - Wikidata - wikimedia - TriplyDB

Is there a role for immunotherapy in HER2-positive breast cancer?

Is there a role for immunotherapy in HER2-positive breast cancer?

http://www.wikidata.org/entity/Q57107866

about

Is there a role for immunotherapy in HER2-positive breast cancer?

http://www.wikidata.org/entity/Q57107866

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Is there a role for immunotherapy in HER2-positive breast cancer?

@en

Is there a role for immunotherapy in HER2-positive breast cancer?

@nl

type

label

Is there a role for immunotherapy in HER2-positive breast cancer?

@en

Is there a role for immunotherapy in HER2-positive breast cancer?

@nl

prefLabel

Is there a role for immunotherapy in HER2-positive breast cancer?

@en

Is there a role for immunotherapy in HER2-positive breast cancer?

@nl

P1433

Q57107866-C34E4C74-88DC-44E2-9C4D-DEBCCBA07C2E

P1476

Q57107866-C9A0451C-C41B-405F-9BDB-76D2882B471C

P2093

Q57107866-16D707CE-2EE8-486A-A4F3-CD0D321F776D

Q57107866-86B5553F-1795-4DFB-9A58-B079B14027CF

Q57107866-ACD80102-62F7-410B-869F-BD45363E120D

Q57107866-F81F317D-B18A-4FB0-92EB-7C463F56B957

P2860

Q57107866-010253DB-5C99-4FDD-BBC7-EF4708E7DF7B

Q57107866-04F0C129-D03C-4A42-BFCA-1DBCA62EE376

Q57107866-11E222C3-7CB1-4C12-8822-A9C4BC370025

Q57107866-184DB416-DA45-4716-91BD-8FFF4DFCF667

Q57107866-20B27F58-9E14-451C-B606-179B045803ED

Q57107866-2F41F87C-3AD3-4A4F-96A0-229B1F56708F

Q57107866-37FA9689-9894-4EE5-B2C2-3AAD06EBEAC3

Q57107866-3FE282CC-D87B-4630-81AF-DB4BBCE59662

Q57107866-4B8D8A9D-B308-4181-B795-485ECC628490

Q57107866-509719A3-8180-4A7C-A5FC-D1A347AD1A9E

P2888

Q57107866-9C290FC9-CC83-4C18-854C-A1A4938A05BE

P304

Q57107866-DA12FEBF-8B62-4CEF-87C2-058F669CB21D

P31

Q57107866-53360DB0-1F82-4BD4-B3DE-E06069DD8816

P356

Q57107866-183C49E8-4058-4526-AFC3-A8BE4812D618

P407

Q57107866-3BBF275B-BB1C-45CD-9523-9B50F4423789

P433

Q57107866-DD979545-2804-4638-9BEA-C1C2470FAB7C

P478

Q57107866-468B236E-A504-4759-B0CF-315BE8370896

P577

Q57107866-191FC00A-7821-4B42-A527-B1301A439472

P698

Q57107866-7BA57175-877F-454B-86EC-FE135684697B

P921

Q57107866-32C9332C-FA1F-4125-96B5-37B68F785214

P932

Q57107866-BDE0ECD3-976C-4C81-8617-3E1EA6D0A733

P356

S41523-018-0072-8

P1433

NPJ breast cancer

P1476

Is there a role for immunotherapy in HER2-positive breast cancer?

@en

P2093

Esther Holgado

http://www.w3.org/2001/XMLSchema#string

Javier Cortes

http://www.w3.org/2001/XMLSchema#string

Jose Perez-Garcia

http://www.w3.org/2001/XMLSchema#string

Maria Gion

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer genome landscapes

Comprehensive molecular portraits of human breast tumours

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

Signatures of mutational processes in human cancer

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.

P2888

s41523-018-0072-8

P304

21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41523-018-0072-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30131972

http://www.w3.org/2001/XMLSchema#string

P921

P932

6093898

http://www.w3.org/2001/XMLSchema#string